<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521843</url>
  </required_header>
  <id_info>
    <org_study_id>12345678</org_study_id>
    <nct_id>NCT03521843</nct_id>
  </id_info>
  <brief_title>LDD in Treatment of Femoropopliteal ISR</brief_title>
  <official_title>Study of Local Drug Delivery in the Treatment of Femoropopliteal In-stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness and safety of local drug delivery using TAPAS
      balloon catheter system in the treatment of femoropopliteal in-stent restenosis. Patients
      with femoropopliteal in-stent restenosis will randomly receive balloon dilation or balloon
      dilation plus local drug delivery using balloon catheter system. Their clinical outcomes
      (e.g. 12-month late lumen loss or late lumen loss at secondary intervention within 12 months,
      6-month and 1-year patency rate of target vessel) in 1 year after the treatment will be
      compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Femoropopliteal occlusive disease is a common type of peripheral arterial disease.
      Endovascular treatment has been the first-line treatment of femoropopliteal occlusive
      disease. However, the in-stent re-stenosis has been a major limitation of well long-term
      patency after stent implantation. The chronic inflammation induced by stenting could be a
      main reason of restenosis. Then the concept &quot;leave nothing behind&quot; is proposed, and some
      novel treatment methods and devices are developed. Here, the investigators propose the
      hypothesis that using local drug delivery with TAPAS balloon system can relieve the
      inflammation induced by the stent implantation and balloon dilation. Therefore, 40 patients
      of femoropopliteal in-stent restenosis will be randomly allocated into the group &quot;balloon
      dilation+local drug delivery with balloon system&quot; or &quot;balloon dilation only&quot;. The 1-year
      patency rate,12-month late lumen loss, incidence of complications, imaging parameters will be
      compared between two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>only the doctors know the group the patient goes into</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>the revascularization rate of target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MLD</measure>
    <time_frame>6 months</time_frame>
    <description>minimal lumen diameter of target vessel at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>restenosis rate</measure>
    <time_frame>6 months</time_frame>
    <description>the rate of re-stenosis (≥50) of target vessel at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of treatment related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford level</measure>
    <time_frame>12 months</time_frame>
    <description>change of Rutherford level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI</measure>
    <time_frame>12 months</time_frame>
    <description>change of ankle brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>main amputation</measure>
    <time_frame>12 months</time_frame>
    <description>rate of main amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month patency rate</measure>
    <time_frame>12 months</time_frame>
    <description>the 12-month patency rate of target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month patency rate</measure>
    <time_frame>6 months</time_frame>
    <description>the 6-month patency rate of target vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late lumen loss rate at secondary intervention</measure>
    <time_frame>12 months</time_frame>
    <description>the rate of late lumen loss of target vessel at secondary intervention within 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>balloon dilation only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balloon dilation+local drug delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon dilation only</intervention_name>
    <description>The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.</description>
    <arm_group_label>balloon dilation only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon dilation+local drug delivery</intervention_name>
    <description>The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.</description>
    <arm_group_label>balloon dilation+local drug delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have signed the informed consent

          -  age of 18-80 years old

          -  femoropopliteal artery disease (Rutherford 2-4)

          -  femoropopliteal in-stent restenosis (≥70%)

          -  length of lesion ≤ 20cm

          -  at least one infrapopliteal run-off vessel

        Exclusion Criteria:

          -  serum Cr &gt; 150 umol/L

          -  patients with acute thrombosis

          -  stent fracture within femoropopliteal artery

          -  allergic to aspirin, heparin, clopidogrel, paclitaxel, contrast medium

          -  already recruited into other clinical trials that could influence the outcome of this
             study

          -  pregnancy and lactation

          -  relatively easy bleeding

          -  malignancy or irreversible organ failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meng Ye, M.D., Ph.D.</last_name>
    <phone>+86 13817145123</phone>
    <email>13817145123@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuofei Yang, M.D., Ph.D.</last_name>
    <phone>+8613764227372</phone>
    <email>doctor_yangshofei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Ye, M.D., Ph.D.</last_name>
      <phone>+86 13817145123</phone>
      <email>13817145123@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>femoropopliteal occlusive disease</keyword>
  <keyword>local drug delivery</keyword>
  <keyword>endovascular treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

